Contributors: Institut Pasteur de la Guyane; Réseau International des Instituts Pasteur (RIIP); Cellule d'Intervention Biologique d'Urgence - Laboratory for Urgent Response to Biological Threats (CIBU); Institut Pasteur Paris (IP); Environnement et Risques infectieux - Environment and Infectious Risks (ERI); Modélisation mathématique des maladies infectieuses - Mathematical modelling of Infectious Diseases; Institut Pasteur Paris (IP)-Centre National de la Recherche Scientifique (CNRS); Centre de Recherche Translationnelle - Center for Translational Science (CRT); Unité des Maladies Infectieuses et Tropicales (UMIT); Centre Hospitalier Andrée Rosemon Cayenne, Guyane Française; Centre Hospitalier de l'Ouest Guyanais Franck Joly Saint-Laurent-du-Maroni, Guyane Française; This study was supported by the European Regional Development Fund under EPI-ARBO grant agreement GY0008695; the Regional Health Agency of French Guiana; and the National Center of Spatial Studies. C. Fl. acknowledges financial support from the Centre National d’Etudes Spatiales-Terre solide, Océan, Surfaces Continentales, Atmosphère fund (grant number CNES-TOSCA-4800000720) and funding from Calmette and Yersin allocated by the Pasteur Institut Department of International Affairs. S. C. acknowledges financial support from the AXA Research Fund, the Investissement d’Avenir program, the Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases program (grant number ANR-10-LABX-62-IBEID), the Models of Infectious Disease Agent Study of the National Institute of General Medical Sciences, the INCEPTION project (PIA/ANR-16-CONV-0005), and the European Union’s Horizon 2020 research and innovation program under ZIKAlliance grant agreement number 734548.; ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010); ANR-16-CONV-0005,INCEPTION,Institut Convergences pour l'étude de l'Emergence des Pathologies au Travers des Individus et des populatiONs(2016); European Project: 734548,ZIKAlliance(2016)
نبذة مختصرة : International audience ; Background: Since the identification of Zika virus (ZIKV) in Brazil in May 2015, the virus has spread throughout the Americas. However, ZIKV burden in the general population in affected countries remains unknown.Methods: We conducted a general population survey in the different communities of French Guiana through individual interviews and serologic survey during June-October 2017. All serum samples were tested for anti-ZIKV immunoglobulin G antibodies using a recombinant antigen-based SGERPAxMap microsphere immunoassay, and some of them were further evaluated through anti-ZIKV microneutralization tests.Results: The overall seroprevalence was estimated at 23.3% (95% confidence interval [CI], 20.9%-25.9%) among 2697 participants, varying from 0% to 45.6% according to municipalities. ZIKV circulated in a large majority of French Guiana but not in the most isolated forest areas. The proportion of reported symptomatic Zika infection was estimated at 25.5% (95% CI, 20.3%-31.4%) in individuals who tested positive for ZIKV.Conclusions: This study described a large-scale representative ZIKV seroprevalence study in South America from the recent 2015-2016 Zika epidemic. Our findings reveal that the majority of the population remains susceptible to ZIKV, which could potentially allow future reintroductions of the virus.
Processing Request
No Comments.